Wordt geladen...
Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers
Emicizumab (ACE910) is a bispecific antibody that is a novel, subcutaneously injectable treatment for patients with hemophilia A. This study assessed the relative bioavailability of emicizumab between old and new drug products (DPs) and among 3 commonly used subcutaneous injection sites (abdomen, up...
Bewaard in:
| Gepubliceerd in: | Clin Pharmacol Drug Dev |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767117/ https://ncbi.nlm.nih.gov/pubmed/30230257 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.617 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|